Subgroups of fibromyalgia;Ein modell zur einteilung des fibromyalgiesyndroms

Schmerz

Volumn 21, Issue 5, 2007, Pages 424-429

  Muller W ^a   Schneider, M ^b   Joos, T ^c   Hsu, H Y ^c   Stratz, T ^a,d,e  

^a Park Klinik   (Germany)

^b Sektion Röntgen und Elektronenbeugung   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Rheumaklinik Bad Säckingen ^*  (Germany)

^e Hospital de Bad Säckingen   (Germany)

Author keywords

5 HT3 receptor antagonist; Antidepressant treatment; Fibromyalgia; Subgroups; Therapy

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; SEROTONIN 3 ANTAGONIST; TROPISETRON; TUMOR NECROSIS FACTOR ALPHA;

BECK DEPRESSION INVENTORY; CHRONIC DISEASE; DEPRESSION; DISEASE CLASSIFICATION; FIBROMYALGIA; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MENTAL DISEASE; NOCICEPTION; PATHOPHYSIOLOGY; PSYCHOTHERAPY; REVIEW; SOMATOFORM DISORDER; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSION; FIBROMYALGIA; HUMANS; PAIN; PSYCHOTHERAPY; SOMATOFORM DISORDERS;

EID: 35748956836     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00482-007-0541-8     Document Type: Review

References (34)

1. Anderberg UM, Martensdottir I, von Knorring L (2000) Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain 4(1): 27-35
2. Arnold LM, Rosen A, Pritchett YL et al. (2005) A randomized double-blind placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depression disorder. Pain 119(1-3): 5-15
3. Biewer W, Conrad I, Hauser W (2004) Fibromyalgia. Schmerz 18(2): 118-124
4. Blumenstiel K, Eich W (2003) Psychosomatic aspects in the diagnosis and treatment of fibromyalgia. Schmerz 17(6): 399-404
5. Burckhardt CS, O'Reilly CA, Wiens AN et al. (1994) Assessing depression in fibromyalgia patients. Arthritis Care Res 7(1): 35-39
6. Conrad I (2003) Diagnosis and clinical signs of fibromyalgia. Schmerz 17(6): 464-474
7. Egle UT (2005) Somatoform disorders - an update. MMW Fortschr Med 147(2): 4-6
8. Färber L, Stratz T, Brückle W et al. (2000) Efficacy and tolerability of tropisetron in primary fiobromyalgia - a highly selective and compeditve 5-HT3 receptor antagonist. Scand J Rheumatol 29 [suppl 113]: 49-54
9. Fiebich BL, Akundi RS, Lieb K et al. (2004) Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheumatol 33: 28-32
10. Gendreau RM, Thorn MD, Gendreau JF et al. (2005) Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32(10): 1975-1985
11. Giesecke T, Williams DA, Harris RE et al. (2004) Subgrouping of fibromyalgia patients on the basis of pressure-pain threshold and psychological factors. Arthritis Rheum 50(8): 2716-2717
12. Hankin HA, Spencer T, Kegerreis S et al. (2001) Analysis of pain behavior profiles and functional disability in outpatient physical therapy clinics. Orthop Sports Ther 31(2): 90-95
13. Hauser W, Bernardy K, Arnold B (2006) Fibromyalgia - a somatoform (pain) disorder? Schmerz 20(2): 128-139
14. Hudson JL, Pope HG jr (1996) The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 22(2): 285-303
15. Koeppe C, Schneider C, Thieme K et al. (2004) The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functionale magnetic resonance imaging pilot study. Scand J Rheumatol 33: 24-27
16. Montoya P, Sitges C, Carcia-Herrera M et al. (2005) Abnormal affective modulation of somatosensory brain processing among patients with fibromyalgia. Psychosom Med 67(6): 957-963
17. Odeh M (1998) Role of cytokines in rheumatoid arthritis. Drug News Perspect 11: 331-341
18. Oen K, Robinson DB, Nickerson P et al. (2005) Familial seropositive rheumatoid arthritis in North American native families: effects of sharped epitope and cytokine genotypes. J Rheumatol 32(6): 983-991
19. O'Malley PG, Balden E, Tomkins G et al. (2000) Treatment of fibromyalgia with antidepressants: a metaanalysis. J Gen Intern Med 15(9): 659-666
20. Persson E, Rivano-Fischer M, Eklund M (2004) Evaluation of changes in occupational performance among patients in a pain management program. Rehabil Med 36(2): 85-91
21. Ploghaus A, Narain C, Beckmann CF et al. (2001) Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci 21(24): 9896-9903
22. Ploghaus A, Tracey I, Gati JS et al. (1999) Diccociating pain from its anticipation in the human brain. Science 284(5422): 1979-1981
23. Salemi S, Rethage J, Wollina U et al. (2003) Dedection of interleukin 1-b (IL-, interleukin-6) and tumor necrosis factor a in skin of patients with fibromyalgia. J Rheumatol 30: 148-150
24. Späth M, Stratz T, Neeck G et al. (2004) Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 33: 267-270
25. Stratz T, Schochat T, Hrycaj P et al. (1994) Die Therapie der generalisierten Tendomyopathie (Fibromyalgie) durch Blockierung der 5-HT3-Rezeptoren. Z Reumatol 53: 335-338
26. Stratz T, Schneider M, Joos T et al. (2006) Are mild inflammatory processes a possible cause of fibromyalgia in a subtype of this syndrome? Submitted
27. Stratz T, Müller W (2002) Schmerzbeeinflussung durch den 5-HT3-Rezeptor-Antagonisten Tropisetron bei sekundären Fibromyalgien. Fortschr Med 120: 17-20
28. Stratz T, Varga B, Müller W (2003) Beeinflusst die Depressivität den Behandlungseffekt von Tropisetron bei Fibromyalgie-Patienten? Z Rheumatol 62: 42-45
29. Stratz T, Müller W (2003) Die Fibromyalgie. Phys Med Rehab Kuror 13: 108-114
30. Thieme K, Turk DC, Flor H (2004) Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med 66(6): 837-844
31. Thieme K, Cromnica-Ihle E, Flor H (2003) Operant behavioral treatment of fibromyalgia; a controlled study. Arthritis Rheum 49(3): 314-320
32. Thomas E, Blotmann F (2001) Are antidepressants effetive in fibromyalgia? Joint Bone Spine 69(6): 531-533
33. Wolfe F, Cathey MA, Hawley DJ (1994) A double-blind placebo-controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 23(5): 255-259
34. Zeitz KP, Guy N, Malberg AB et al. (2002) The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci 22: 1010-1019